OLMA Olema Pharmaceuticals Inc
Price (delayed)
$5.1
Market cap
$348.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.2
Enterprise value
$210.45M
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is
Highlights
Olema Pharmaceuticals's equity has soared by 106% from the previous quarter and by 61% YoY
The debt has declined by 41% year-on-year and by 16% since the previous quarter
OLMA's quick ratio is up by 49% since the previous quarter but it is down by 14% year-on-year
Olema Pharmaceuticals's net income has decreased by 34% YoY and by 6% from the previous quarter
OLMA's EPS is down by 2.8% YoY
Key stats
What are the main financial stats of OLMA
Market
Valuations
Earnings
Shares outstanding
68.33M
Market cap
$348.5M
Enterprise value
$210.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.71
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$142.26M
Net income
-$129.47M
EBIT
-$129.47M
EBITDA
-$127.93M
Free cash flow
-$104.51M
Per share
Balance sheet
Liquidity
EPS
-$2.2
EPS diluted
-$2.2
Free cash flow per share
-$1.78
Book value per share
$7.14
Revenue per share
$0
TBVPS
$7.68
Total assets
$450.98M
Total liabilities
$42.02M
Debt
$1.43M
Equity
$408.96M
Working capital
$396.72M
Debt to equity
0
Current ratio
10.5
Quick ratio
10.4
Net debt/EBITDA
1.08
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-43.2%
Return on equity
-48.3%
Return on invested capital
-60.5%
Return on capital employed
-31.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OLMA stock price
How has the Olema Pharmaceuticals stock price performed over time
Intraday
1.8%
1 week
15.38%
1 month
18.06%
1 year
-49.75%
YTD
-12.52%
QTD
35.64%
Financial performance
How have Olema Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$142.26M
Net income
-$129.47M
Gross margin
N/A
Net margin
N/A
The operating income has decreased by 36% YoY and by 4.7% QoQ
Olema Pharmaceuticals's net income has decreased by 34% YoY and by 6% from the previous quarter
Growth
What is Olema Pharmaceuticals's growth rate over time
Valuation
What is Olema Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.71
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OLMA's EPS is down by 2.8% YoY
Olema Pharmaceuticals's equity has soared by 106% from the previous quarter and by 61% YoY
OLMA's price to book (P/B) is 70% less than its last 4 quarters average of 2.4 and 68% less than its 5-year quarterly average of 2.2
Efficiency
How efficient is Olema Pharmaceuticals business performance
Olema Pharmaceuticals's ROE has increased by 10% from the previous quarter but it has decreased by 8% YoY
The return on assets has grown by 10% since the previous quarter but it has declined by 5% year-on-year
The return on invested capital has grown by 4.6% since the previous quarter and by 3.2% year-on-year
Dividends
What is OLMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OLMA.
Financial health
How did Olema Pharmaceuticals financials performed over time
Olema Pharmaceuticals's total assets has soared by 96% from the previous quarter and by 63% YoY
Olema Pharmaceuticals's total liabilities has soared by 82% YoY and by 34% from the previous quarter
The debt is 100% smaller than the equity
Olema Pharmaceuticals's equity has soared by 106% from the previous quarter and by 61% YoY
Olema Pharmaceuticals's debt to equity has shrunk by 100% QoQ and by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.